Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 23 and 24, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on January 23, 2025, at a weighted average price of $10.49 per share.
• He also sold 2,000 shares of common stock on January 24, 2025, at a weighted average price of $10.89 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these sales, Ma directly owns no shares, but indirectly owns 2,899,138 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales by an insider. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider stock sales. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any material non-public information. It is common for executives to use these plans for diversification or liquidity purposes.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates